Hydrochloric Acid → 7-fluoro-6-[6-(1-piperidin-4-yl-1H-pyrazol-4-yl)imidazo[1,2-b]pyridazin-3-ylmethyl]-quinoline
反応式
C(OC([N:8]1[CH2:13][CH2:12][CH:11]([N:14]2[CH:18]=[C:17]([C:19]3[CH:20]=[CH:21][C:22]4[N:23]([C:25]([CH2:28][C:29]5[CH:30]=[C:31]6[C:36](=[CH:37][C:38]=5[F:39])[N:35]=[CH:34][CH:33]=[CH:32]6)=[CH:26][N:27]=4)[N:24]=3)[CH:16]=[N:15]2)[CH2:10][CH2:9]1)=O)(C)(C)C.Cl.C([O-])(O)=O.[Na+]>O1CCOCC1>[F:39][C:38]1[CH:37]=[C:36]2[C:31]([CH:32]=[CH:33][CH:34]=[N:35]2)=[CH:30][C:29]=1[CH2:28][C:25]1[N:23]2[N:24]=[C:19]([C:17]3[CH:16]=[N:15][N:14]([CH:11]4[CH2:12][CH2:13][NH:8][CH2:9][CH2:10]4)[CH:18]=3)[CH:20]=[CH:21][C:22]2=[N:27][CH:26]=1参加物
5
反応物 3
生成物 1
試薬・触媒・溶媒 1
実験手順
4-{4-[3-(7-Fluoro-quinolin-6-ylmethyl)-imidazo[1,2-b]pyridazin-6-yl]-pyrazol-1-yl}-piperidine-1-carboxylic acid tert-butyl ester (Stage 180.1, 850 mg, 1.611 mmol) was stirred 1 h at rt in dioxane (15 mL) with HCl in dioxane (4 M, 4,03 mL). The RM was then basified with saturated NaHCO3 aqueous sol. and the dioxane was evaporated. The resulting aqueous sol. was extracted 3 times with DCM containing 10% EtOH. Combined organic layers were dried and evaporated and the residue was purified by flash chromatography (CombiFlash® Companion System®, with RediSep® silica gel column, DCM/MeOH with ammonia=100:0->90:10) to afford the title compound (tR 3.04 min (conditions 3), MH+=428).
後処理
- customthe dioxane was evaporated
- extractionThe resulting aqueous sol. was extracted 3 times with DCM containing 10% EtOH
- customCombined organic layers were dried
- customevaporated
- customthe residue was purified by flash chromatography (CombiFlash® Companion System®, with RediSep® silica gel column, DCM/MeOH with ammonia=100:0->90:10)
出典と根拠
- ORDレコード
- ord-c4846dfc79484648b50f8647cab58306
- 出典データセット
- uspto-grants-2014_09
- 特許番号
- US08822468B2
反応ノート
読み込み中…